TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02014740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT03254654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
Study: NCT00005950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study: NCT04246801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Study: NCT01083524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate Sodium
Description: 3 mg po bid for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate Sodium
Description: 6.25 mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate Sodium
Description: 12.5 mg po bid
Study: NCT02201121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation
Description: This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
Study: NCT03574857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone Oral Tablet
Description: Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorothiazide Injection
Description: Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
Study: NCT01882842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
Study: NCT00175877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study.
Study: NCT02748330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel
Study: NCT01591525

Intervention type: BEHAVIORAL
Intervention: Education on regular visits to a Primary Care Provider
Description: one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.

Intervention type: BEHAVIORAL
Intervention: Education on regular visits to a Primary Care Provider
Description: one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
Study: NCT03524508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onivyde
Description: The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/LV
Description: The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
Study: NCT00389259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV placebo q4h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo q4h
Study: NCT01875094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Management / MTM using Health IT
Study: NCT01455701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as indicated in the arm description.
Study: NCT01093157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenocorticotrophic hormone ACTH
Description: There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
Study: NCT02748330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Acetylsalicylic acid
Study: NCT00348920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Spinal and General Anesthesia
Description: Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
Study: NCT02867124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-NTX
Description: Vivitrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Description: Vivitrol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: place of residence
Description: One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: opioid treatment program
Description: One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
Study: NCT03163784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Inoculum Capsule
Description: Sieved fecal matter prepared in glycerol/saline solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Inoculum Capsule
Description: Sieved fecal matter prepared in glycerol/saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Fecal Inoculum Capsule)
Description: Placebo capsule manufactured to mimic Fecal Inoculum Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Antibiotic pre-treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic Placebo
Description: Placebo tablets manufactured to mimic antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Placebo
Description: Placebo tablets manufactured to mimic antibiotics
Study: NCT02730052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omron 9200T plus Telemonitoring
Description: Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omron 9200T without Telemonitoring
Description: Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
Study: NCT01089998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose (18F)-IBA
Description: Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
Study: NCT01937598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients administered a single dose of placebo during a mixed meal challenge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients administered a single dose of placebo during a mixed meal challenge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal test
Description: Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal test
Description: Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Patients administered a single dose of Sitagliptin during a mixed meal challenge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Patients administered a single dose of Sitagliptin during a mixed meal challenge.
Study: NCT03404284

Intervention type: BEHAVIORAL
Intervention: Family planning and infant immunization service integration
Description: The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
Study: NCT01700270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib (TKI258)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: perpetrator drug; 7 days of dosing
Study: NCT01713270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic denervation
Description: Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drug
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct-Current Cardioversion
Description: After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
Study: NCT02116257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol
Description: total 4g of Propacetamol added to patient's PCA regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PCA regimen
Study: NCT04173884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constructive Feedback
Description: Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constructive Feedback
Description: Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
Study: NCT01763151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toric IOL
Description: implantation of an aspheric, toric, acrylic IOL during cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL combined with opposite clear corneal incision (OCCI)
Description: aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
Study: NCT02018198

Intervention type: DIAGNOSTIC_TEST
Intervention: FebriDx
Description: Point of Care Host Immune Response Test

Intervention type: DIAGNOSTIC_TEST
Intervention: FebriDx
Description: Point of Care Host Immune Response Test
Study: NCT01665547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-carnitine
Description: 3gm l-carnitine from day 1 to day 12 of the menstrual cycle
Study: NCT05406843

Intervention type: OTHER
Intervention: Preoperative cognitive functions of participants undergoing open heart surgery
Description: Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.

Intervention type: OTHER
Intervention: Postoperative cognitive functions of particiants undergoing open heart surgery
Description: Changes in mini mental test scores were recorded in the postoperative period.
Study: NCT02846350

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision
Study: NCT03654976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet
Description: Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet, for daily administration (1 tablet per day)
Study: NCT01811784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask people not to drink raw sap

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask people not to drink sap or drink sap from skirt protected trees
Description: Behavioural

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Study: NCT00110981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: Three times a week (TIW) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanerept
Description: 50 mg subcutaneously twice weekly (SC BIW) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
Study: NCT01572675

Intervention type: DRUG
Intervention: etorocoxib
Description: Administered as 30 mg or 60 mg oral film-coated tablets

Intervention type: DRUG
Intervention: celecoxib
Description: Administered as 100 mg or 200 mg oral hard capsules
Study: NCT03470038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Intramuscular injection
Study: NCT00201669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
Study: NCT04158921

Intervention type: OTHER
Group type: OTHER
Intervention: Control:Diabetes mobile app
Description: The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. \> 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.